Latest GlaxoSmithKline Stories

Aeras Signs Agreement with GSK to Jointly Advance TB Vaccine

2012-10-09 23:20:19

Phase IIb Proof of Concept Trial Planned for Kenya, India and South Africa ROCKVILLE, Md., Oct. 10, 2012 /PRNewswire-USNewswire/ -- Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01(E)(*) adjuvant. This novel research and resource-sharing agreement between the largest non-profit TB vaccine biotech and...

New Higher Dose Bupropion Extended-Release Tablets Now Available

2012-10-09 07:27:32

AUSTIN, Texas, Oct. 9, 2012 /PRNewswire/ -- Edgemont Pharmaceuticals, LLC, a neuroscience-focused company, today announced that Forfivo(TM) XL (bupropion hydrochloride extended-release tablets) is now available nationwide for the treatment of major depressive disorder (MDD). Forfivo XL is the only extended-release bupropion HCl product to offer a once-daily, 450mg dose in a single tablet. (Photo - http://photos.prnewswire.com/prnh/20121009/NY88522 ) "Until now, most patients in...

National Survey Uncovers the Truth About Cold Sores, Finds Women Go to Great Lengths to Conceal

2012-10-04 02:27:14

PARSIPPANY, N.J., Oct. 4, 2012 /PRNewswire/ -- GlaxoSmithKline Consumer Healthcare today released results from a new national survey of female cold sore sufferers, revealing that cold sores impact many dimensions of a woman's life, including everyday activities, relationships and confidence. Women report feeling self-conscious (86 percent), unattractive (77 percent) and embarrassed (72 percent) with a cold sore. In fact, two-thirds of women say a cold sore feels like the worst...

Epizyme Earns $4 Million in Milestone Payments in GlaxoSmithKline Alliance to Discover and Develop Novel HMT Therapeutics

2012-10-03 02:27:49

Alliance Focuses on Novel, Small Molecule Therapeutics Targeting Epigenetic Enzymes for the Treatment of Cancer and Other Diseases CAMBRIDGE, Mass., Oct. 3, 2012 /PRNewswire-USNewswire/ -- Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for patients with genetically defined cancers, announced today $4 million in milestone payments from collaborator GlaxoSmithKline (GSK) based on the achievement of pre-clinical milestones. In 2011, Epizyme...

2012-10-02 02:30:21

YARDLEY, Pa., Oct. 2, 2012 /PRNewswire/ -- OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered Bi-Directional(TM) nasal technology. In a direct comparison of drug absorption, the study found that OptiNose's sumatriptan product sent 62% more drug into the blood in the critical first 15 minutes than Imitrex(®) nasal spray (AUC (0-15) = 1.69 ng*hr/mL and 1.04 ng*hr/mL,...

The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, GlaxoSmithKline, AstraZeneca, Merck and Pfizer

2012-09-24 06:26:55

CHICAGO, Sept. 24, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Dr. Reddy's Laboratories (NYSE:RDY), GlaxoSmithKline (NYSE:GSK), AstraZeneca (NYSE:AZN), Merck & Co. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Get...

GlaxoSmithKline initiates a multi-city conversation focused on improving the health of US communities

2012-09-24 02:26:25

PHILADELPHIA, Sept. 24, 2012 /PRNewswire/ -- GlaxoSmithKline plc [LSE/NYSE: GSK] today launched a national initiative to examine the barriers and identify opportunities to build healthier communities in the United States. The program kicks off with "A Conversation on Community Health," hosted by The Atlantic, in Philadelphia at WHYY studios. This is the first of three events taking place in US cities to explore what it means, and what it takes, to be a healthy community. GSK is...

Response Genetics Raises $8.8 Million in Financing

2012-09-13 02:27:50

LOS ANGELES, Sept. 13, 2012 /PRNewswire/ -- Response Genetics, Inc. (Nasdaq: RGDX) announced today that it has entered into a purchase agreement with GlaxoSmithKline and one of its existing significant stockholders to raise $8.8 million from the private placement of 8,000,000 newly issued shares of its common stock at a purchase price of $1.10 per share. The signing of the purchase agreement and closing of the financing occurred today, Thursday, September 13, 2012. "We are...

Circassia Appoints Dr Brett Haumann as Chief Medical Officer

2012-09-10 22:23:22

OXFORD, England, September 11, 2012 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Dr Brett Haumann as Chief Medical Officer. Dr Haumann joins Circassia from GlaxoSmithKline where he was Vice President and Medicines Development Leader responsible for the late-stage development of once-daily inhaled medicines for the treatment of asthma and COPD. "I am delighted Brett has chosen to join...

Wockhardt launches generic version of anti-depressant drug Wellbutrin® SR

2012-09-04 06:27:25

PARSIPPANY, N. J. and MUMBAI, India, Sept. 4, 2012 /PRNewswire/ -- Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 100 mg, 150 mg and 200 mg 12-Hr extended release tablets of Bupropion HCl which is used in the treatment of depression. Bupropion is the generic name for the brand Wellbutrin(®) SR, marketed in the U.S. by Glaxo Smithkline. Wockhardt is launching the product...